ijms-logo

Journal Browser

Journal Browser

Molecular Advances in Melanoma Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 648

Special Issue Editor

Special Issue Information

Dear Colleagues,

Melanoma is a major global health issue and represents up to 5.5% of all skin cancers worldwide. It arises from melanocytes found in the epidermis, and chronic inflammation, genetic factors and sun exposure contribute to the formation of melanoma. Malignant melanoma spreads rapidly and can swiftly invade nearby tissues, progressing to the lymph nodes and metastasizing to other organs. Early diagnosis and treatment are crucial to patient survival. Various systemic drug therapies target the immunogenic aspects of this cancer. Traditional immunotherapy, such as TNFα and immune checkpoint inhibitors, is also widely used in the treatment of melanomas. Recently, significant interest from multidisciplinary research groups worldwide has emerged in seeking to utilize nonconventional remedies, such as cannabinoids, to treat melanoma.

The aim of this Special Issue is to extend the knowledge of current remedies employed in the treatment of melanoma. Methodological studies focusing on new models as well as research techniques used to study these aspects are also welcome.

Dr. Terrence Piva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • anti-cancer
  • immunotherapy
  • targeted therapy
  • signaling pathway
  • Polyphenolic compounds
  • cannabinoids
  • pharmacotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 361 KiB  
Review
Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations
by Walid Shalata, Zoe Gabrielle Attal, Adam Solomon, Sondos Shalata, Omar Abu Saleh, Lena Tourkey, Fahed Abu Salamah, Ibrahim Alatawneh and Alexander Yakobson
Int. J. Mol. Sci. 2024, 25(11), 5794; https://doi.org/10.3390/ijms25115794 - 26 May 2024
Viewed by 457
Abstract
Melanoma, a malignant neoplasm originating from melanocytes, stands as one of the most prevalent cancers globally, ranking fifth in terms of estimated new cases in recent years. Its aggressive nature and propensity for metastasis pose significant challenges in oncology. Recent advancements have led [...] Read more.
Melanoma, a malignant neoplasm originating from melanocytes, stands as one of the most prevalent cancers globally, ranking fifth in terms of estimated new cases in recent years. Its aggressive nature and propensity for metastasis pose significant challenges in oncology. Recent advancements have led to a notable shift towards targeted therapies, driven by a deeper understanding of cutaneous tumor pathogenesis. Immunotherapy and tyrosine kinase inhibitors have emerged as promising strategies, demonstrating the potential to improve clinical outcomes across all disease stages, including neoadjuvant, adjuvant, and metastatic settings. Notably, there has been a groundbreaking development in the treatment of brain metastasis, historically associated with poor prognosis in oncology but showcasing impressive results in melanoma patients. This review article provides a comprehensive synthesis of the most recent knowledge on staging and prognostic factors while highlighting emerging therapeutic modalities, with a particular focus on neoadjuvant and adjuvant strategies, notably immunotherapy and targeted therapies, including the ongoing trials. Full article
(This article belongs to the Special Issue Molecular Advances in Melanoma Therapy)
Back to TopTop